中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.021 seconds)

    VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION
    1.
    发明申请
    VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION 审中-公开

    公开(公告)号：WO2022169895A1

    公开(公告)日：2022-08-11

    申请号：PCT/US2022/014970

    申请日：2022-02-02

    Applicant: GEOVAX, INC. ,  LEIDOS, INC.

    Inventor： HAUSER, Mary Jo ,  DOMI, Arban ,  GUTIERREZ, Gabriel ,  PANNUCCI, James ,  KOTRAIAH, Vinayaka ,  PHARES, Timothy ,  BUONTEMPO, Peter ,  BROWNE, Cecille

    IPC: A61K35/768 ,  C12N15/86 ,  C12N15/87 ,  C12N15/90

    Abstract: The invention provides virus-based expression vectors comprising immune-checkpoint inhibitor inserts for use as effective adjuvants in enhancing T-cell priming to an antigen in a host during a vaccination regimen. In particular, the compositions described herein are novel recombinant modified vaccinia Ankara (MVA) viral constructs encoding one or more peptides which, upon administration, are expressed in a multimer conformation and subsequently cleaved and secreted from the cell. Such peptides are capable of downregulating an immune checkpoint pathway, for example, by inhibiting the activation of programmed-cell death protein 1 (PD-1), programed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or another immune checkpoint regulator, or a combination thereof. When used in concert with the administration of an antigen during a vaccination strategy, the immune checkpoint expressing MV A viral construct provides significantly improved antigen-specific CD8+ T cell expansion, increased antigenic responses, and improved vaccination efficacy.

    PD-1 AND CTLA-4 DUAL INHIBITOR PEPTIDES
    2.
    发明申请
    PD-1 AND CTLA-4 DUAL INHIBITOR PEPTIDES 审中-公开

    公开(公告)号：WO2018218137A1

    公开(公告)日：2018-11-29

    申请号：PCT/US2018/034625

    申请日：2018-05-25

    Applicant: LEIDOS, INC.

    Inventor： GUTIERREZ, Gabriel M. ,  KOTRAIAH, Vinayaka ,  PHARES, Timothy ,  PANNUCCI, James

    IPC: C07K14/705 ,  A61K38/17

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

Patent Agency Ranking